Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Withdrawn 2 Unknown 2 Active not recruiting 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Stomach Neoplasms 1 Sarcoma, Clear Cell 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms by Site 1 Multiple Myeloma 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Digestive System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Adenocarcinoma 1

Interventions

Carboplatin 44 Paclitaxel 43 liposomal doxorubicin 23 Topotecan 19 Gemcitabine 18 pembrolizumab 17 Cyclophosphamide 17 Bevacizumab 16 Cisplatin 12 niraparib 9 olaparib 8 fludarabine 7 Taxes 7 Docetaxel 7 aldesleukin 6 Nivolumab 6 Doxorubicin 6 1-dodecylpyridoxal 6 oregovomab 5 fludarabine phosphate 5 Peripheral Blood Stem Cell Transplantation 5 Filgrastim 5 rucaparib 4 durvalumab 4 avelumab 4 Surgical Procedures, Operative 4 Melphalan 4 Ipilimumab 4 Interleukin-2 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Ovarian Neoplasms × dostarlimab × Clear all

NCT03955471 2022-09-10

MOONSTONE

Tesaro, Inc.

Phase 2 Terminated

41 enrolled 22 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡